Melanoma Clinical Trial
Official title:
A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
The primary objective of this study will be to determine the toxicity and Maximum Tolerated Dose (MTD) of the combination of high dose aldesleukin and sorafenib in previously untreated patients with metastatic or unresectable clear cell renal carcinoma (RCC) and metastatic melanoma.
Rationale: Previous research indicates that high dose aldesleukin produces tumor regression
through upregulation of the patients' immune system. Research suggests that sorafenib
directly targets tumors by inhibiting angiogenic activity with possibly some cytotoxicity.
Angiogenic refers to the formation of new blood vessels that support tumor growth.
Cytotoxicity is the measurement of a chemical's ability to damage or kill cancer cells.
Researchers have hypothesized that the complementary ways aldesleukin and sorafenib work,
and their non-overlapping toxicity profiles, may create a reasonable combination for the
treatment of metastatic renal cell carcinoma and metastatic melanoma. The current Phase I
study will evaluate toxicity in patients through assessing various dose levels of sorafenib
in combination with aldesleukin.
Purpose: The primary objective is to determine the maximum tolerated dose and characterize
the toxicity of high dose aldesleukin and sorafenib in patients with unresectable or
metastatic clear cell renal carcinoma and metastatic melanoma. Secondary objectives include
determining progression free survival in patients, evaluating in a preliminary manner
response rates, and assessing other measurements in study participants.
Treatment: Study participants will be given bolus high dose aldesleukin and sorafenib.
Aldesleukin will be provided through intravenous infusions on days 1 through 5. Each 5 day
treatment is considered a cycle. The second cycle of aldesleukin will start on day 15. Two
cycles are considered 1 course. All study participants will be given the same dose level of
aldesleukin. No dose reductions will be permitted. Sorafenib will then be administered on
day 29. Since this study will assess the maximum tolerated dose of sorafenib, some study
participants will receive different amounts of this drug compared to others depending upon
when each individual enrolls in the study. Each group of 3 to 6 study participants will
receive a higher dose of sorafenib until the maximum tolerated dose is established.
Imagining studies will be performed to determine response to treatment during week 12. If
the patient has stable or responding disease, a second course will be administered on the
same schedule. Patients without disease response will be given one additional course of
aldesleukin past maximal response. When it is decided that no further aldesleukin will be
provided to patients, sorafenib at the Food and Drug Administration approved dose may be
continued until there is a lack of clinical benefit or intolerable side effects develop.
Several tests and exams will be given throughout the study to closely monitor patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|